Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-SUCRALFATE - TAB 1G | 1G | TABLET | Resolved | 2022-09-09 | 2023-09-22 | 169045 |
| APO-SUCRALFATE - TAB 1G | 1G | TABLET | Resolved | 2017-09-06 | 2018-09-11 | 21096 |
| APO-SUCRALFATE - TAB 1G | 1G | TABLET | Resolved | 2020-01-22 | 2020-03-09 | 103923 |
| APO-SUCRALFATE - TAB 1G | 1G | TABLET | Actual shortage | 2025-02-06 | 2025-02-06 | 249763 |
| APO-SULFATRIM ORAL SUSPENSION | 40MG 8MG | SUSPENSION | Actual shortage | 2017-08-13 | 2017-10-05 | 18991 |
| APO-SUMATRIPTAN | 50MG | TABLET | Resolved | 2017-06-28 | 2017-08-30 | 14247 |
| APO-SUMATRIPTAN | 50MG | TABLET | Resolved | 2023-03-16 | 2023-03-30 | 187235 |
| APO-SUMATRIPTAN | 100MG | TABLET | Resolved | 2021-10-08 | 2021-12-22 | 146913 |
| APO-SUMATRIPTAN | 50MG | TABLET | Resolved | 2020-06-24 | 2020-08-17 | 118778 |
| APO-SUMATRIPTAN | 50MG | TABLET | Resolved | 2018-04-02 | 2018-11-02 | 44517 |
| APO-SUMATRIPTAN | 100MG | TABLET | Resolved | 2018-04-10 | 2018-11-03 | 45350 |
| APO-SUMATRIPTAN | 50MG | TABLET | Resolved | 2023-07-21 | 2023-09-15 | 199539 |
| APO-SUMATRIPTAN | 50MG | TABLET | Resolved | 2023-12-01 | 2023-12-15 | 212380 |
| APO-SUMATRIPTAN | 100MG | TABLET | Resolved | 2024-03-08 | 2024-04-19 | 221732 |
| APO-SUMATRIPTAN | 50MG | TABLET | Resolved | 2024-03-15 | 2024-04-19 | 222464 |
| APO-SUMATRIPTAN | 100MG | TABLET | Resolved | 2021-01-18 | 2021-02-05 | 131889 |
| APO-TADALAFIL | 5MG | TABLET | Resolved | 2020-10-28 | 2021-01-26 | 127376 |
| APO-TADALAFIL | 5MG | TABLET | Resolved | 2023-02-09 | 2023-02-23 | 184109 |
| APO-TADALAFIL | 5MG | TABLET | Resolved | 2019-03-05 | 2019-04-26 | 77896 |
| APO-TADALAFIL | 10MG | TABLET | Resolved | 2019-03-20 | 2019-04-26 | 79051 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |